Based on the results for January–November 2025, Russian consumers purchased 21 million packs of drugs from the hepatoprotectors and lipotropic agents group (A05B under the EphMRA classification). Over the year, physical consumption within this group increased by 7.6%. In value terms, sales of hepatoprotectors during the reporting period grew by 19% and reached RUB 27.6 billion (at retail prices, including VAT). Growth in sales of liver-protective medicines has continued for the second consecutive year. In 2024, physical demand in the group rose by 6% compared with 2023, while consumer spending increased by 18%. After the surge observed in 2022, the pharmaceutical market entered a period of stagnation, which was also reflected in hepatoprotector sales: in 2023, physical demand within the group declined by 3% versus 2022, while value sales nevertheless increased by the same 3%.

According to the Audit of Retail Sales of Medicines in Russia (total sell out) database of RNC Pharma, the average price per pack of a hepatoprotective medicine in January–November 2025 exceeded RUB 1,300. At the same time, prices within the group range widely—from around RUB 150 to RUB 12,000 per pack. Each year, the average price level in this category increases by approximately 10%, driven by both a shift in demand toward higher-priced products and the inflationary factor.

Peak demand for hepatoprotectors over the eleven months of 2025 was recorded in March, when Russians purchased around 2.1 million packs worth RUB 2.8 billion. Retail demand for this group of medicines was also elevated in January, October, and November 2025, with more than 2 million packs sold in each of these months. The lowest sales volumes were observed during the summer period; for example, in June, sales amounted to approximately 1.68 million packs.

The majority of sales value within the analyzed group is generated by ademetionine-based products, which during the reporting period accounted for more than 47% of total value sales and 35% of physical sales volume. In addition, phospholipid-based medicines play a significant role in the category, including combinations with glycyrrhizic acid and multivitamins. Taken together, these products form more than 30% of value sales and 34% of physical sales volume in the hepatoprotector market.

As of January–November 2025, more than 50 hepatoprotector brands were present in retail sales. The leading position during this period was retained by Heptral (INN: ademetionine) from Abbott, which accounted for over 36.2% of total consumer spending in the category. Compared with January–November 2024, the brand demonstrated growth of 18% in value terms and 12% in physical units. Second place was held by Essentiale (INN: phospholipids) from Sanofi, with a 16.2% market share and value growth of 16%. The top three was completed by the Russian product Phosphogliv from Pharmstandard, containing glycyrrhizic acid in combination with phospholipids; during the reporting period, the product accounted for 12.1% of value sales in the group and showed value growth of 21%.

Among the top ten brands, only one recorded a decline in value sales: Liv-52 from Himalaya lost 6% of its value sales year-on-year, while physical demand for the product fell by 17%. The highest growth rates among leading products were observed for the domestic medicine Heptzifol (INN: ademetionine) from Pharmasyntez, which ranked tenth in the category; over the year, sales of this brand increased threefold.

Table. Sales volume and dynamics of hepatoprotectors (group A05B under the EphMRA classification) on the Russian retail pharmaceutical market in 2022–2024 and January–November 2025.